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Abstract
Background: Childhood obesity is associated with the early development of diseases such as type 2 diabetes and
cardiovascular disease. Unfortunately, to date, traditional methods of research have failed to identify effective
prevention and treatment strategies, and large numbers of children and adolescents continue to be at high risk of
developing weight-related disease.
Aim: To establish a unique ‘biorepository’ of data and biological samples from overweight and obese children, in
order to investigate the complex ‘gene × environment’ interactions that govern disease risk.
Methods: The ‘Childhood Overweight BioRepository of Australia’ collects baseline environmental, clinical and
anthropometric data, alongside storage of blood samples for genetic, metabolic and hormonal profiles.
Opportunities for longitudinal data collection have also been incorporated into the study design. National and
international harmonisation of data and sample collection will achieve required statistical power.
Results: Ethical approval in the parent site has been obtained and early data indicate a high response rate among
eligible participants (71%) with a high level of compliance for comprehensive data collection (range 56% to 97%
for individual study components). Multi-site ethical approval is now underway.
Conclusions: In time, it is anticipated that this comprehensive approach to data collection will allow early
identification of individuals most susceptible to disease, as well as facilitating refinement of prevention and
treatment programs.
Background
Obesity in early life is associated with many adverse
effects on health including an increased risk of type 2 dia-
betes (T2DM), heart and liver disease [1]. In the majority
of cases, weight gain is attributable to lifestyle-related fac-
tors [2], although a strong genetic contribution to body
weight regulation is also recognised [3,4]. Since the first
rare single-gene mutations were identified in severe
early-onset obesity, far more common variants in key
genes (and/or their promoter sequences) have been
identified which explain significant weight variability
within the population [5]. Most susceptibility alleles
probably have only a small direct effect [6], instead acting
to determine future disease risk mainly by their interac-
tion with environmental exposures [7]. This process may
occur through environmental modulation of gene expres-
sion (without alteration of the underlying genomic
sequence) in a process known as ‘epigenetics’ [8].
Numerous genes have been identified through genome
wide association studies (GWAS) and candidate gene
approaches that appear to be associated, either directly
or indirectly, with the regulation of body weight [9]. It is
likely that, through a process of natural selection, these
g e n e sh a v eb e c o m em o r ep r e v a l e n td u et ot h ee v o l u -
tionary advantage that they offer by promoting energy
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our obesogenic environment, however, these genetic
susceptibility traits are now associated with an increased
risk of obesity and associated metabolic diseases, such
as Type 2 diabetes.
The majority of genes identified in monogenic cases of
obesity appear to be involved in the central regulation of
energy intake. In this regard, the most strongly repli-
cated candidate gene has been the melanocortin 4
receptor, which ha been suggested to be responsible for
up to 6% of cases of severe, early onset obesity [10], but
also likely contributes to population variations in body
fat, adipose tissue distribution, some metabolic traits
and childhood weight gain [11]. Genes involved with
energy utilization have also been implicated in common
obesity, with replicated associations shown for genes
encoding b-adrenergic receptors 2 and 3, hormone-sen-
sitive lipase, and mitochondrial uncoupling proteins 1, 2,
and 3 [12]. The FTO gene is another example of a key
gene that appears to be responsible for population-wide
variations in body weight and composition [13], and
represents just one of many genes identified in recent
times [14]. This is a rapidly progressing field of research,
in terms of both the identification of new genes and the
role that they play in both adult and early onset weight
gain [15-17].
The role of epigenetics in body weight regulation is
less clear, however, and remains the focus of intense
interest [18]. Epigenetic factors include several different
classes of modified nucleotides and proteins that inter-
act to regulate the activity state of underlying DNA
sequence. Such factors are usually heritable throughout
cell division and play a pivotal role in specifying cell fate
and function. The methylation of specific CpG dinucleo-
tides (the most widely studied epigenetic mark) is
known to affect gene expression and to be sensitive to
environmental disruption, including dietary change
[19-23]. Epigenetic profile is modifiable during critical
developmental periods [23-26] and is involved in several
obesity-related metabolic pathways [26,27]. Epigenetic
analyses, including DNA methylation profiling, thus
offers a compelling new paradigm for how early nutri-
tion may impact upon later obesity [28] and, although
studies assessing the role of DNA methylation in human
obesity are rare [29,30], the challenge is to now develop
specific studies aimed at investigating how environmen-
tal exposures interact with underlying genetic determi-
nants to dysregulate gene expression and lead to
metabolic disorders [31].
While societal change could theoretically solve the
problem of childhood obesity, current endeavours have
not proven fruitful in the long-term [32] and millions
remain at high risk of developing weight-related disease
over the next decade. Public health initiatives to combat
childhood obesity must be complemented by effective
identification and management programs for individuals
at high risk of developing weight-related disease.
Childhood obesity and its relationship with health-related
complications
Interactions between obesity, genetics and the environ-
ment may be important not only to the development of
obesity itself but also to its co-morbidities. For example
while obese individuals are more likely to develop cardi-
ovascular disease, once the disease is established then
obesity may actually offer some protection against its
adverse outcomes [33] - a paradox coined ‘reverse epi-
demiology’. Furthermore, investigation of weight-related
co-morbidities in adult populations has revealed a sub-
population of metabolically ‘healthy’ obese individuals
[34]. It is not yet clear whether such individuals will
continue to remain disease-free, or whether this pheno-
type represents delayed disease onset.
Regardless, this phenotype is relevant to how we
approach the obesity epidemic in youth: specifically,
some children with excess adiposity will remain disease-
free while others will go on to have metabolic disease in
their teenage years or in young adulthood. As the
demand for intensive weight management treatment
vastly exceeds the available supply, some method of effi-
caciously allocating limited resources must be devel-
oped. Additionally, identifying factors that predict
weight-related co-morbidities may lead to strategies to
prevent such complications at the population or primary
care level, thus giving patients and practitioners more
time to resolve the underlying weight problems.
Understanding the complex interactions involved in
the development of weight-related disease necessitates a
holistic approach to research, rather than the more tradi-
tional ‘reductionist’ mode. In a ‘systems biology’
approach, investigations are used to systematically study
complex interactions in biological systems [35]. Until
very recently, this has been impractical for the study of
human obesity but such endeavours are now becoming
possible through major technical and computational
advances. Furthermore, there has been an increasing
recognition within the scientific community that it is
important to gather complementary data across cohorts,
both to increase sample size and to avoid bias for popula-
tion generalization [36,37]). Together, these approaches
offer a unique opportunity to the study of complex ‘gene
× environment’ (G×E) interactions. ‘Nutrigenomics’ (the
field of research assessing the effect of nutrition on gene
expression) is one important example [38].
To date, most clinical research has centred around
either identifying genetic susceptibility in specific groups
of obese children [39] or studying the impact of specific
environmental factors on weight gain [40]. To fully
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weight-related disease, however, studies should combine
comprehensive phenotypic description (ideally incorpor-
ating clinical physical examination), with the capacity to
examine genetic/metabolic/proteomic characteristics and
accurate measures of environmental exposure. To disen-
tangle associations from potentially causative factors,
such studies would recruit initially disease-free over-
weight/obese youth for standardised clinical longitudinal
follow-up to identify important clinical endpoints as
they develop.
What can a Biorepository offer for the study of childhood
obesity?
A biorepository acts as a library of biological and asso-
ciated data from large numbers of individuals, either
from the general population or from specific groups of
individuals with a condition of interest. Moving beyond
isolated sample collection, biorepositories now comprise
comprehensive and sophisticated data warehouses con-
taining biological material, results from associated bio-
chemical investigations, detailed participant-level
information (e.g. self-completed questionnaires and clin-
ical records) and area-level variables (e.g. measures of
environmental exposures).
Such initiatives should, in due course, provide the
necessary statistical power to detect relatively small
direct effects (odds ratios of the order of 1.15 to 1.3)
that will nonetheless be of clinical significance and be
directly relevant to public health [41]. There are now
many established biobanks, with examples being the
Western Australia Genome Project (http://www.genepi.
org.au/projects/waghp.html) and the UK Biobank
(http://www.ukbiobank.ac.uk). Each aims to recruit
enough individuals for stand-alone genetic association
studies, although future international harmonisation of
national biobanks (e.g. through ventures such as the
Promoting Harmonisation of Epidemiological Biobanks
in Europe (PHOEBE); http://www.populationbiobanks.
org) will further increase statistical power [41].
The investigation of complex childhood weight issues
should similarly benefit by routinely and prospectively
‘biobanking’ blood samples (and possibly other biofluids
such as urine and saliva) alongside longitudinal data
from sufficient numbers of overweight and obese youth.
No such biobank has yet been established. This manu-
script describes the initial phase of establishing the
‘Childhood Overweight BioRepository of Australia’
(termed ‘COBRA’). The aim in publishing protocols at
this early stage is to enable harmonisation and colla-
boration with other centres who may be considering
such investigations. It is hypothesised that, given suffi-
ciently harmonised data and a multidisciplinary, interna-
tional, multi-site approach, COBRA will ultimately
enable systems biology investigations of the effects of
excess adiposity from childhood across multiple biologi-
cal pathways, including the G×E interactions that impact
on these molecular networks.
Which specific questions will be addressed within
COBRA?
Initial investigations will consist of cross-sectional ana-
lyses of prevalent cases (comparing those with and with-
out co-morbidities at initial assessment). Longitudinal
data collection will enable investigations of incident
cases (those who subsequently develop co-morbidities)
and those who remain disease free (controls). Specific
objectives of COBRA are outlined below:
1. Identification of factors associated with increased risk of
weight-related co-morbidity at initial presentation
There is a high prevalence of adverse health problems
within cohorts of overweight children. For example,
abnormal glucose metabolism (i.e. either impaired fast-
ing glucose or impaired glucose tolerance) is present in
approximately 10% of obese youth, whereas the meta-
bolic syndrome is present in as many as 1-in-4 obese
individuals attending specialist services [42]. While dis-
crepancies in diagnostic criteria for the latter lead to
some variation around this figure, a diagnosis of meta-
bolic syndrome in pre-adult years is highly significant
[43]. A biorepository designed to identify risk factors
associated with weight-related complications, and the
development and assessment of appropriate screening
and treatment strategies to prevent or delay co-morbid-
ity onset, would greatly assist clinical management.
2. Determination of how environmental, genetic and
metabolic factors come together to confer an increased risk
of future disease
With prospective data collection, it will be possible to
begin to discriminate temporal relationships between
G×E ‘clusters’ and development of specific co-morbid-
ities. These data should inform service delivery and
allow appropriate management strategies to be focussed
to those most at-risk. COBRA will build upon evidence
from existing research strategies that are examining
gene by nutrition interactions (http://www.nugo.org/)
and physical activity by metabolism interactions (http://
www.earlybirddiabetes.org/index.php) in healthy non-
obese adults and children respectively, as well as gene
by nutrition interactions in obese adults (http://www.
nugenob.com/). The project carves an important niche
in this regard.
3. Identification of factors associated with success in long-
term weight loss and maintenance
With prospective data collection, it will be possible to
identify factors associated with success in controlling
weight and avoidance of long-term disease. Within
intensive weight management programs some children
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change [44-46]. Some of this resistance is likely to be
due to complex individual family, lifestyle, societal and
cultural factors, but there is also evidence that metabolic
[47], genetic [48,49] and environmental factors [44] also
impact upon potential ‘success’. While the US National
Weight Control Registry (http://www.nwcr.ws/) has
yielded important and unexpected information for over-
weight adults, there is no comparable information for
children. The extensive baseline phenotyping undertaken
in COBRA offers such an opportunity for similar studies
in children.
This manuscript outlines the initial phases of develop-
ment of COBRA, with details of study design and preli-
minary data relating to uptake.
Methods
Participants: Who should be approached for inclusion?
COBRA was established to investigate the development
of weight-related co-morbidity, rather than the devel-
opment of obesity per se, and therefore it targets popu-
lations with established obesity. Sites that can support
in-depth clinical assessment are best placed to join
COBRA although the project was designed using a
‘modular’ format so that it is sufficiently flexible to
cope with variations in the specific study components
that can be implemented according to feasibility at the
local site.
A tt h ep a r e n ts i t e( T h eR o y a lC h i l d r e n ’sH o s p i t a l
(RCH), Melbourne, Australia), all overweight and obese
patients referred to the Weight Management Service are
approached for enrolment. For the purposes of recruit-
ment, overweight and obesity is classified using the 85
th
and 95
th percentile cut-offs of US-derived data produced
by the Centres for Disease Control and Prevention
(http://www.cdc.gov), as these data are routinely used
on growth charts in Australia. When it comes to longi-
tudinal analysis, there are a range of alternative systems
for classification (e.g. International Obesity Task Force
criteria, or World Health Organisation recommenda-
tions) and these may continue to evolve over time.
Therefore, the COBRA dataset will always include raw
height, weight and BMI data, so that other classifications
can be used flexibly and as appropriate. All children and
adolescents (up to age 17.99 years) are approached, with
no minimum age for recruitment recognising that, rea-
listically, very few (if any) children are referred and rou-
tinely managed through specialist weight management
services before the age of 2 years.
With 200-250 new patients each year, this is the lar-
gest tertiary-hospital based service within the limited
services offered across Australia [50]. The spectrum of
care follows that of other tertiary hospital paediatric
weight management services [46]. Routine clinical care
involves three-monthly patient visits. In addition to
patients with established co-morbidities at initial presen-
tation, a significant proportion develop co-morbidities
over time, such as insulin resistance, dyslipidaemia and
h y p e r t e n s i o n .S o m eg oo nt od e v e l o pe s t a b l i s h e dd i s -
eases such as type 2 diabetes and the metabolic syn-
drome [51] in adolescence/early adult life. These will act
as cases to the ‘healthy’ overweight/obese controls
within the setting of a prospective cohort study.
Recruitment is also being undertaken, with specific
ethical approval, within a National Health and Medical
Research Council (NHMRC)-funded Randomised Con-
trolled Trial that is currently assessing a ‘shared care’
approach to the management of childhood obesity (Aus-
tralian Clinical Trials Registry 12608000055303; http://
www.rch.org.au/ccch/research.cfm?doc_id=12126). Two
additional clinical centres and one population-based
cohort study (that includes a significant clinical exami-
nation component) are also currently applying for site-
specific ethical approval to join the COBRA project.
While longitudinal data collection is not a prerequisite
for COBRA uptake, it is emphasised to disentangle tem-
poral associations of future disease.
Measures: What data should COBRA collect?
A biorepository needs to balance comprehensive data
collection against a patient’sc l i n i c a ln e e d sa st h i sc o u l d
jeopardise either recruitment or long-term follow-up.
Furthermore, data collection should not adversely
impact upon, or drive, routine clinical treatment proto-
cols. Measures should include comprehensive assess-
ment of environmental exposure, alongside collection of
biosamples that will allow a systems biology approach
through genetic, epigenetic and metabolic testing. Accu-
rate anthropometry is vital, as are detailed data on clini-
cal management and follow-up.
Multi-centre data pooling and analysis requires univer-
sal agreement relating to key measures. Perhaps the big-
gest challenge is obtaining agreement on which measures
of energy intake and expenditure to collect. Such harmo-
nisation can be enhanced by communication across net-
w o r k so fe x p e r t s ,s u c ha st h e‘Australasian Child and
Adolescent Obesity Research Network’ (ACAORN;
http://www.acaorn.med.usyd.edu.au/) and the German
competence network of obesity (Kompetenznetz Adiposi-
tas) of the German ministry of Research and Education
(http://kn-adipositas.de/knadipositas/default.aspx).
Data collection components employed in COBRA can
be summarised as those relating to environment,
anthropometry and clinical evaluation, and biological
samples, plus long-term follow-up clinical data. These
are described in more detail below and in Table 1.
a) Environmental measures collected within COBRA
are primarily collected through self-completed
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dated and/or are standardised and widely used. COBRA
participants complete questionnaires at home in the
week preceding the initial clinical appointment. These
include a parent questionnaire, a child questionnaire
(for those aged 11 years and older), a food frequency
questionnaire, and a 3-day food diary. Parent and child
questionnaires are available as supplementary material
Table 1 Parameters collected for each participant within COBRA.
Self-completed participant information
Domain: Instrument/Source (respondent
1)
Clinical exam Blood samples
￿ Health: Self-rated health (P, C)
￿ Concern with weight: HopSCOTCH
2 (P)
￿ Help seeking: HopSCOTCH
2 (P)
￿ Pregnancy & birth: HopSCOTCH
2, LSAC
3, NHS
4 (P)
￿ Early nutrition: LSAC
3 (P)
￿ Family health history: HopSCOTCH
2 (P)
￿ Mental health: SDQ
5 (P, C); Kessler 10
6 (P, C)
￿ Enjoyment of physical activity (PA): LEAP
7 (P, C)
￿ Active/Sedentary time: HopSCOTCH
2, LSAC
3 (P, C)
￿ Targeted nutrition/PA: HopSCOTCH
2 (P, C)
￿ Transport, biking, walking: IPAQ
8 (P, C)
￿ Childcare: HopSCOTCH
2 (P)
￿ Sleep habits: LSAC
3 (P, C)
￿ Neighbourhood: LSAC
3, ALSPAC
9, NEWSA
10 (P, C)
￿ Socio-demographic: Census (P)
￿ Household composition: FLAME
11 (P)
￿ Nutrition: 3-day prospective food diary (P, C); ACAES
12 (P, C)
￿ Quality of life (QoL): PedsQL Core module
13 (P, C); Sizing Them Up
14 (P);
Sizing Me Up
15 (C)
￿ MARCA
16: 24-hour PA recall
Clinical history
￿ Specific details relating to weight
￿ Other health issues
￿ Peri natal and Past Medical History
￿ Medications (past and present)
￿ Allergies
￿ Immunisations
￿ Developmental history and schooling
￿ Family history
￿ Sleep issues
Clinicalpathology
￿ Oral Glucose
Tolerance Test
￿ Fasting glucose
￿ Fasting Insulin
￿ Lipid profile
￿ Thyroid
function test
￿ Liver function
tests
￿ Iron studies
￿ Full blood
count
￿ Haemoglobin
A1C
￿ Vitamin D
￿ Vitamin B12
￿ Magnesium
￿ Calcium
￿ Phosphate
￿ Folate
Clinical examination
￿ General appearance (dysmorphism, affect, body
proportions)
￿ Cardiovascular examination including blood
pressure
￿ Respiratory examination
￿ Abdominal examination
￿ Skin (acne, hirsutism, acanthosis nigricans,
intertrigo, striae)
￿ Pubertal assessment (method of Tanner and
Whitehouse)
Research assays
Anthropometry See Table 2
Notes: In addition to self-completed survey items, participants wear an
accelerometer, which is an omni-directional device to record child’s
movement in 15 second intervals over 9 days. О
￿ Height (measured to nearest
￿ 0.1 cm using a stadiometer)
￿ Weight
￿ Waist circumference
￿ Bioimpedence (measure of % fat by body
quadrant, fat free mass, & basal metabolic rate)
1P = parent, C = child (most instruments are completed by children approximately aged 11 years and older, exceptions are QoL instruments and accelerometry).
Data sources indicated in bold are validated instruments.
2HopSCOTCH is an NHMRC-funded clinical intervention trial of shared care for paediatric obesity currently being undertaken at RCH/MCRI (http://www.rch.org.au/
ccch/research.cfm?doc_id=12126).
3Longitudinal Study of Australian Children (http://www.aifs.gov.au/growingup/).
4National Health Survey 2004/05 (http://www.abs.gov.au/).
5Strengths & Difficulties Questionnaire (http://www.sdqinfo.com/).).
6Kessler 10 [66]..
7Live Eat and Play Study [67].
8International Physical Activity Questionnaire (http://www.ipaq.ki.se/ipaq.htm).
9Avon Longitudinal Study of Parents and Children (Children of the 90’s; http://www.bristol.ac.uk/alspac/).
10Neighborhood Environment Walkability Scale Abbreviated (sections C-H; http://www.activelivingresearch.org/node/10649): only administered to 13+ yo.
11FLAME–A New Zealand study to identify risk factors for obesity in children [68].
12The Australian Child & Adolescent Eating Survey food frequency questionnaire (ACAES FFQ), [69].
13PedsQL - Measurement model for the Pediatric Quality of Life Inventory (http://www.pedsql.org/).
14’Sizing Them Up’ [70].
15’Sizing Me up’ [71].
16Multimedia Activity Recall for Children & Adolescents (MARCA) [72]: this instrument is currently waiting to be implemented into the study protocol.
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9, 10, 11, 12, 13, 14). Children aged five years and older
also complete a specific child survey upon clinical pre-
sentation (interviewer-administered for the youngest
children). At this time, parents also complete the par-
ent-reported version of these instruments so that items
and reference periods are synchronised between parents
and child.
b) Biological samples are collected for both clinical
and research applications. RCH Weight Management
S e r v i c ec l i n i c a lp r o t o c o l si n c l u d ear o u t i n ep a n e lo f
pathology examinations that is subject to minor modifi-
cation based on individual clinical presentation. It
includes: (i) metabolic profiles (including liver function
tests, lipid profiles, insulin and glucose [fasting in under
10 year olds and as part of an oral glucose tolerance test
in over 10 year olds]), and (ii) nutritional assessment
(iron stores, B group vitamins, Vitamin D, folate, cal-
cium, phosphate, magnesium).
Research specimens are collected at the same time as
clinical pathology samples to minimise patient burden
and distress. Table 2 outlines the protocol for research
biological sample collection and storage. These samples
are then biobanked for future investigation which will
include: (i) metabolic analyses (e.g. adiponectin, leptin,
resistin), (ii) genetic analysis, (iii) gene expression analy-
sis, and (iv) epigenetic analysis in peripheral blood
mononuclear cells. Genetic analyses will include major
susceptibility loci for weight-related co-morbidities such
as T2DM [52], lipid abnormalities [53] and the meta-
bolic syndrome [54], as well as larger-scale genome-
wide association studies. Expression profiling, by high
throughput quantitative RT-PCR, will include assess-
ment of mRNA expression of known target genes
involved in obesity, type 2 diabetes, metabolism and
inflammation, while DNA microarray analysis may
potentially reveal novel gene pathways significantly
a l t e r e di no v e r w e i g h tc h i l d r e na th i g h e s tr i s ko fm e t a -
bolic complications. Epigenetic analysis will include
assessment of DNA methylation of CpG dinucleotides
involved in the regulation of gene expression, as this is
strongly influenced by environmental factors. Biobanked
samples are currently stored within the Murdoch Chil-
drens Research Institute Biobanking Facility, which will
ultimately be housed in the Children’s BioResource Cen-
tre in the new Royal Children’s Hospital in Melbourne.
As COBRA moves to multi-site data collection, local
s i t e sw i l ln e e dt oa s s e s st h efeasibility of maintaining
biospecimen locally or centralising sample storage using
existing COBRA infrastructure.
c) Anthropometry and clinical data collection includes
baseline and at least bi-annual measures of height,
weight, waist circumference, total and regional fat and
muscle mass (using a body composition analyser (cur-
rently BC-418, Tanita Corporation, Tokyo, Japan)),
blood pressure and pubertal status. Additionally, the
initial consultation collects detailed information relating
to the presence of weight-related co-morbidities.
d) Longitudinal follow-up data are collected through
clinic re-attendance up until patients reach 18 years of
age. These clinic visits are scheduled at equally spaced
intervals (initially 3 monthly), with routine clinical data
collected (including Auxology, all details relating to
attempts at weight management, other clinical events,
and results of routine repeat clinical investigations). Fol-
low-up in adulthood for the parent organisation will be
enabled through participation in BioGrid (http://www.
biogrid.org.au/wps/portal), a Victorian data-linkage
resource that can identify and facilitate access to data
on medical visits at other participating hospitals or
health administration datasets maintained by the Victor-
ian Department of Health. As such data linkage
resources may not be available for other national or
international centres, and recognising that some chil-
dren will fail to reattend follow-up appointments,
COBRA has also incorporated a ‘consent to re-contact’
procedure should participants be lost to follow up
through standard clinical contact.
The process of recruitment, along with data and sam-
ple collection, is shown as a flowchart in Figure 1.
Table 2 COBRA Biobank sample collection.
Biospecimen fractions & number/volume of stored aliquots
Participant age Type of collection tube Guthrie cards Peripheral whole blood Plasma Lymph-ocytes Granulo-cytes Sera
>= 3 years EDTA 4 × 0.1 ml 2 × 1 ml 3 × 1 ml 2 × 1 ml
SG 6 × 0.5 ml
LH 4 × 1 ml 4 × 0.5 ml
Citrate 4 × 0.25 ml
<3 years EDTA 4 × 0.1 ml 2 × 1 ml 2 × 1 ml
SG 4 × 0.5 ml
LH 2 × 1 ml 2 × 0.5 ml
Citrate 3 × 0.25 ml
Number of samples × volume collection. ml = millilitre(s). EDTA = EthyleneDiamineTetraAcetic acid tube. SG = Serum Gel tube. LH = Lithium Heparin tube.
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to local patient confidentiality constraints) using the
Western Australian Genetic Epidemiology Resource (an
NHMRC Enabling Facility; http://www.wager.org.au/) or
similar resource. This facility provides rigorous patient
privacy and confidentiality safeguards, especially in rela-
tion to the transmission of electronic information, com-
bined with the ability to customise access to specific
data components (e.g. individual variables) and/or
patient data (e.g. subsets of participants).
What is the anticipated attrition?
Obesity management is associated with notoriously poor
compliance [55]. Therefore steps that improve rates of fol-
low-up and clinic attendance will improve the quality of
longitudinal data. In a recent audit of the RCH Weight
Management Service, non-attendance was 20% (cancella-
tions 7%, failure to attend without prior notice 13%) over
a 3 ½ year period. This high rate of patient treatment
attendance is predominantly due to the addition of a clinic
co-ordinator who contacts patients and ensures that all
clinic appointment times are filled. While these figures
appear favourable for the parent organisation, there may
be large inter-site variations in clinic compliance.
Ethical issues
COBRA, or any comparable childhood biorepository,
involves complex ethical issues. These include data col-
lection from minors, long-term storage of biological
samples for subsequent genetic analysis, participant
expectations, data protection and privacy, data linkage,
and unspecified consent. These issues have been exten-
sively reported elsewhere [56-59]. Despite these complex
challenges, there is widespread support for projects that
will benefit the public good [60]. COBRA has been
approved at the parent site by the RCH Human
Research Ethics Committee and current COBRA investi-
gators can provide support, in terms of access to
approved ethical documents and consent forms, to other
investigators seeking to join this initiative. Fully
informed and written consent is obtained in all cases.
Sample size and statistical power
Studies of G×E interactions require large sample sizes.
At a population level, the study of G×E interactions in
disease development requires tens of thousands of sub-
jects and is driven by the low frequency of disease
within the population (e.g. the UK Biobank - http://
www.ukbiobank.ac.uk/). Conversely, however, much
smaller numbers are required when the prevalence of
the condition of interest is much higher within the
study population. Therefore, biobanking samples from
groups of individuals who are at much higher risk of
disease (e.g. overweight youth or those with a family
history of disease) is likely to be as productive as popu-
lation-based biobanks, in terms of the number of cases
identified, at a much smaller total sample size [61].
Data on the specific contribution of genetic, environ-
mental, and G×E interactions to the development of
co-morbidities in obese youth is not currently available
- this is one reason for initiating COBRA. Sample size
estimates for COBRA were therefore developed based
on hypothetical combinations of at-risk allele frequen-
cies, environmental exposure prevalence and magnitude
of G×E interactions. The sample size estimates are
applicable to logistic regression models (to estimate the
size of G×E interaction on dichotomous endpoints
defined by disease status), and Cox’s proportional
hazards models (to analyse time until disease occurrence
estimating the increase in the instantaneous rate of dis-
ease) resulting from the G×E interaction.
Table 3 presents the predicted power under several
scenarios. This indicates that with 1000 children,
COBRA will have 80% power to detect G×E interactions
at the 5% level of significance in half of the modelled
combinations. This improves substantially with a sample
size approaching 2000 subjects. Given current national
and international uptake of COBRA, it is anticipated
that this will be achievable within 3-5 years.
The proportion of participants with specific adverse
health problems will be reported with 95% confidence
intervals. Allele frequencies and presence of environ-
mental factors of interest will also be summarised.
Logistic regression models and Cox proportional
hazards models for binary and time to event outcomes
respectively, will be fitted to identify the risk and protec-
tive factors (predictor variables) for health problems and
long-term disease (outcomes) for obese children.
Logistic and Cox regression models will be fitted to
test the hypothesis that the effect of specific alleles on
the risk of developing adverse health problems and
long-term diseases is modified by the presence of select
environmental factors (i.e. is the size of the odds ratio
(or hazard ratio) between a particular gene and a speci-
fic health problem dependent upon whether the envir-
onmental risk factor is present). In these models the
gene and environment variables (both categorical) will
be used in the model as predictor variables in addition
to a variable that represents the interaction between the
gene and environment variables. The p-value for the
gene-by-environment interaction variable will be used to
quantify evidence against the hypothesis that there is no
effect modification (interaction).
Where the effects of the gene on the disease are not
in opposing directions within the categories of the envir-
onmental exposure, evidencef o rag e n e - d i s e a s ee f f e c t
will be quantified using a simultaneous (or “joint”)
hypothesis test
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effects. There is recent evidence that this joint test, as
opposed to a test of the gene variable alone in a simple
marginal gene-disease model, improves power for
detecting a gene effect - even in the presence of a
degree of misclassification in the environmental mea-
sures [62]. The results from the interaction tests, supple-
mented by the joint tests where appropriate, will clarify
the nature of the specific gene-disease associations.
Results
Data collection for COBRA at the RCH Weight Man-
agement Service was initiated in late April 2009. In the
first nine months, 116 patients were approached for
study participation. Of these, 24% cancelled or repeat-
edly failed to attend their appointment and were subse-
quently excluded. Of the 87 remaining patients, 25%
declined participation, 67% consented to COBRA, and
8% are currently being recruited.
Table 4 presents demographic information and
response rates for the first ten months of recruitment.
Of the 77 eligible families that have attended their initial
Weight Management Service appointment, early findings
indicate lower participation rates among adolescents.
Completion rates for the various individual compo-
nents of baseline data collection are as follows: (a) Par-
ent Survey 1, 85%; (b) Child Survey 1, 91%; (c) Parent
Survey 2, 85%; (d) Child Survey 2, 97%; (e) food fre-
quency questionnaire, 93%, (f) 3-day food diary, 56%; (g)
accelerometry, 92%; and, (h) venous blood sample, 73%
(with an additional 11% scheduled). This indicates that,
despite reports in the literature indicating high rates of
treatment non-adherence, families that participate in
COBRA demonstrate a high rate of baseline data
completion.
Some follow-up visits have already occurred, but data
relating to these have not yet been analysed.
Discussion
The establishment of a biorepository of data and biologi-
cal samples from large numbers of overweight and obese
children, alongside longitudinal data collection relating
to co-morbidities, offers a unique opportunity to examine
the complex G×E interactions that likely govern long-
term disease risk in children and adolescents.
One of the primary strengths of COBRA is that it
incorporates comprehensive baseline clinical phenotyp-
ing with longitudinal follow up. Future investigations
may be incorporated through (a) on-going clinical fol-
low-up by established tertiary treatment services, or (b)
Table 3 Power to detect Gene × Environment (G×E) interactions.
SAMPLE SIZE = 1000 SAMPLE SIZE = 2000
G×E interaction OR = 2 G × E interaction OR = 2
Allele frequency (%) Binary environmental exposure prevalence (%) Binary environmental exposure prevalence (%)
20 30 40 20 30 40
10 37.6% 45.8% 49.5% 64.2% 74.6% 78.6%
20 49.8% 58.9% 62.2% 79.0% 87.1% 89.4%
30 50.4% 58.7% 61.2% 79.6% 87.0% 88.7%
G × E interaction OR = 2.5 G × E interaction OR = 2.5
Allele frequency (%) Binary environmental exposure prevalence Binary environmental exposure prevalence
20 30 40 20 30 40
10 57.2% 67.9% 72.3% 85.7% 92.9% 95.0%
20 72.6% 81.7% 84.3% 95.2% 98.2% 98.7%
30 73.3% 81.3% 83.1% 95.5% 98.1% 98.5%
G × E interaction OR = 3 G × E interaction OR = 3
Allele frequency (%) Binary environmental exposure prevalence Binary environmental exposure prevalence
20 30 40 20 30 40
10 71.4% 81.9% 85.7% 94.7% 98.2% 99.0%
20 85.9% 92.5% 94.1% 99.0% 99.8% 99.9%
30 86.6% 92.2% 93.1% 99.1% 99.8% 99.8%
OR = odds ratio. Disease prevalence is 25% throughout. Magnitude of associations between binary outcome and each of the gene and environmental risk factors
are 1.6 throughout. Condition is assumed to be dominant throughout. Figures in bold represent scenarios where sufficient power for the study will be achieved.
Table 4 COBRA response rates by age and gender.
Sex Age ranges (years)
Total number M F <5 5-10 11-18
Eligible (%) 77 41 (53) 36 (47) 6 (8) 34 (44) 37 (48)
Enrolled (%) 55 30 (55) 25 (45) 6 (11) 25 (45) 24 (44)
Declined (%) 22 11 (50) 11 (50) 0 (0) 9 (41) 13 (59)
Participants with upcoming initial appointments (n = 3) and families currently
being recruited (n = 7) have been excluded from these results.
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tion. Multi-site input, both nationally and internation-
ally, will allow specific investigation of G×E effects in
diverse populations, as well as allowing analysis of
comparative effectiveness of different site-specific
treatment modalities. Additionally, combining research
biospecimen collection (for storage in the bioreposi-
tory) with pathology examinations required for clinical
care has resulted in (a) access to specialist phleboto-
mists available through the tertiary paediatric care sec-
tor, (b) reduced patient distress, and (c) a high
proportion of patients successfully contributing
research samples. Routine clinical follow up has also
resulted in on-going contact with families and multiple
opportunities to collect and query self-completed ques-
tionnaire responses, as indicated by high response rates
for this component.
The primary potential weakness of COBRA is low
recognition of childhood obesity by parents [63] and
health professionals [64] as well as a paucity of well-
resourced services for referred children [50]. Further-
more, as COBRA recruitment occurs within specialist
centres, selection bias from recruitment of only treat-
ment-seeking individuals will occur. There may also be
variation in allele frequencies between sites due to dif-
ferences in the underlying population substructure.
While this may increase samples sizes required for the
analysis of G×E interactions, it may also provide infor-
mation on potential confounding due to ancestry and
facilitate identification of different G×E interactions
across different sites/countries.
Conclusions
To date, current strategies aimed at both the preven-
tion and treatment of childhood obesity, and espe-
cially within primary care settings, have largely failed
to deliver expected results [65]. This could lead to a
pandemic of weight-related disease unless novel
modes of research are urgently developed to prevent
and treat those most at risk. Recent technological
advances now allow a ‘wider’ approach to the study of
factors that govern weight status and disease risk in
young people. A biorepository of data and biological
samples from a large cohort of obese children and
adolescents will become a valuable resource over
time, enabling investigation of paediatric precursors
to adult disease.
M a n ym a yb eo ft h eo p i n i o nt h a tt h ep r o b l e mo f
childhood obesity does not require this intense level of
investigation. Some argue that the problem can be easily
solved with more prescriptive measures to modify life-
styles of young children. All attempts at this to date,
however, have inexorably failed in the long-term. It is
therefore time to rethink strategy, with biorepository-
based initiatives likely to prove an invaluable resource in
years to come.
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